Journal Article10.1016/S0041-1345(98)00315-7
Optimal Time Points for the Prediction of the Area-Under-The-Curve in Liver Transplant Patients Receiving Tacrolimus
M. Cantarovich,J. Fridell,J. Barkun,P. Metrakos,Besner Jg,M. Deschenes,E. Alpert,Z. Aalamian,J. I. Tchervenkov +8 more
- 01 Jun 1998
- Vol. 30, Iss: 4, pp 1460-1461
26
About: The article was published on 01 Jun 1998. The article focuses on the topics: Area under the curve & Transplantation.
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation.
TL;DR: Critics have started to question current reliance on trough measurement during therapeutic drug monitoring, with instances of toxicity and rejection occurring when trough concentrations are within ‘acceptable’ ranges, and controversy exists as to whether this will provide any great benefit, given the added complexity in monitoring.
871
A Review on Therapeutic Drug Monitoring of Immunosuppressant Drugs
Niloufar Mohammadpour,Sepideh Elyasi,Naser Vahdati,Amir Hooshang Mohammadpour,Jamal Shamsara +4 more
TL;DR: Therapeutic monitoring of immunosuppressive therapy with cyclosporine is a critical requirement because of intra- and inter-patient variability of drug absorption, narrow therapeutic window and drug induced nephrotoxicity.
59
Immunosuppressant drugs – the role of therapeutic drug monitoring
Atholl Johnston,David W. Holt +1 more
TL;DR: The purpose of this review is to examine the current strategies in use for the therapeutic drug monitoring of immunosuppressant drugs and to discusssome of the factors that impinge on the monitoring of these drugs.
Evaluation of limited sampling methods for estimation of tacrolimus exposure in adult kidney transplant recipients
Katherine A. Barraclough,Nicole M. Isbel,Carl M. J. Kirkpatrick,Katie J. Lee,Paul J. Taylor,David W. Johnson,Scott B. Campbell,D. R. Leary,Christine E. Staatz +8 more
TL;DR: Limited sampling methods better predict tacrolimus exposure compared with C(0) measurement, and several LSSs based on sampling taken 2 h or less post-dose predicted exposure with acceptable bias and imprecision.
Tacrolimus pharmacokinetics and dose monitoring after lung transplantation for cystic fibrosis and other conditions.
Christiane Knoop,Philippe Thiry,Franck Saint-Marcoux,Annick Rousseau,Pierre Marquet,Marc Estenne +5 more
TL;DR: Patients with CF have a higher tacrolimus oral clearance, but nonsignificant differences in short‐term inter‐ and intrasubject variability of exposure compared to patients without CF.
44
References
A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK506 Kidney Transplant Study Group
TL;DR: Tacrolimus is more effective than cyclosporine in preventing acute rejection in cadaveric renal allograft recipients, and significantly reduces the use of antilymphocyte antibody preparations.
1.1K
Multicenter randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of renal allograft rejection - A report of the European Tacrolimus Multicenter Renal Study Group
AD Mayer,Jean-Paul Squifflet +1 more
TL;DR: A significant reduction in the incidence of episodes of allograft rejection observed with tacrolimus therapy may have important long-term implications given the prognostic influence of rejection on graft survival.
759
Pharmacokinetics of tacrolimus in liver transplant patients.
William J. Jusko,Wojciech Piekoszewski,Goran B. Klintmalm,Mark S. Shaefer,Mary F. Hebert,Antoni A. Piergies,Charles C. Lee,Paul J. Schechter,Qais A. Mekki +8 more
TL;DR: The pharmacokinetics of the immunosuppressive agent tacrolimus (FK 506) in liver transplant patients is characterized to characterize the pharmacological action of this drug in patients with liver transplants.
241